Literature DB >> 20470235

Response to Swinnen et al.

Alan C Moses, Christoph Koenen.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20470235      PMCID： PMC2928703          DOI： 10.1089/dia.2009.0186

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN： 1520-9156            Impact factor:   6.118


× No keyword cloud information.
  28 in total

1.  Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

Authors:  K Raslová; M Bogoev; I Raz; G Leth; M-A Gall; N Hâncu
Journal:  Diabetes Res Clin Pract       Date:  2004-11       Impact factor: 5.602

2.  Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.

Authors:  T Haak; A Tiengo; E Draeger; M Suntum; W Waldhäusl
Journal:  Diabetes Obes Metab       Date:  2005-01       Impact factor: 6.577

3.  Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes.

Authors:  Sanne G H A Swinnen; Frank J Snoek; Marie-Paule Dain; J Hans DeVries; Joost B L Hoekstra; Frits Holleman
Journal:  Diabetes Technol Ther       Date:  2009-11       Impact factor: 6.118

4.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

5.  Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Authors:  David Russell-Jones; Richard Simpson; Birgitte Hylleberg; Eberhard Draeger; Jan Bolinder
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

6.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

7.  Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Authors:  Helena W Rodbard; Paul S Jellinger; Jaime A Davidson; Daniel Einhorn; Alan J Garber; George Grunberger; Yehuda Handelsman; Edward S Horton; Harold Lebovitz; Philip Levy; Etie S Moghissi; Stanley S Schwartz
Journal:  Endocr Pract       Date:  2009 Sep-Oct       Impact factor: 3.443

8.  Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine.

Authors:  Satish K Garg; Peter A Gottlieb; Mary E Hisatomi; Anna D'Souza; Andrew J Walker; Kenneth E Izuora; H Peter Chase
Journal:  Diabetes Res Clin Pract       Date:  2004-10       Impact factor: 5.602

9.  Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.

Authors:  Andreas Fritsche; Matthias Axel Schweitzer; Hans-Ulrich Häring
Journal:  Ann Intern Med       Date:  2003-06-17       Impact factor: 25.391

10.  Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

Authors:  Tim Heise; Leszek Nosek; Birgitte Biilmann Rønn; Lars Endahl; Lutz Heinemann; Christoph Kapitza; Eberhard Draeger
Journal:  Diabetes       Date:  2004-06       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.